Skip to main content

Advertisement

Table 4 Adverse events "likely" or "definitely" related to study treatment

From: Safety and performance of Hydros and Hydros-TA for knee osteoarthritis: a prospective, multicenter, randomized, double-blind feasibility trial

System organ class Preferred term Synvisc-one n = 32 Hydros n = 32 Hydros-TA n = 34
Musculoskeletal and Connective Tissue disorders, n (%) Arthralgia 5 (16) 4 (13) 1 (3)
Joint Stiffness 2 (6) 2 (6) 0
Joint Swelling 1 (3) 0 0
General Disorders and Administration Site conditions, n (%) Application Site Warmth 1 (3) 0 0
Injection Site Warmth 0 0 1 (3)
Injection Site Movement Impairment 0 1 (3) 0
Injection site pain 0 0 1 (3)
Total Related Adverse Events,
n (%)
NA 9 (28) 7 (22) 3 (9)